Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Helps Predict Which Heart-Failure Patients Will Worsen Within a Year

By HospiMedica International staff writers
Posted on 19 Mar 2026

Heart failure remains one of the leading causes of illness and death worldwide, with nearly half of patients dying within five years of diagnosis. More...

Despite advances in treatment, predicting how a patient’s condition will evolve remains a major challenge. Researchers have now developed an artificial intelligence (AI) model that can forecast worsening heart function up to a year in advance using routine ECG data.

The deep learning model called PULSE-HF, developed by researchers from MIT (Cambridge, MA, USA), Mass General Brigham (Boston, MA, USA), and Harvard Medical School (Boston, MA, USA), is designed to predict changes in left ventricular function in patients with heart failure. PULSE-HF analyzes electrocardiogram data to predict whether a patient’s left ventricular ejection fraction will fall below 40 percent within the next year. Ejection fraction reflects how effectively the heart pumps blood, with normal values typically ranging from 50 to 70 percent. A decline below 40 percent indicates severe heart failure.

The model was trained and tested using data from three patient cohorts, including Massachusetts General Hospital, Brigham and Women’s Hospital, and the MIMIC-IV database. Across these datasets, the model demonstrated strong predictive performance, achieving AUROC scores between 0.87 and 0.91. Notably, a version of the model using single-lead ECG data performed as well as the standard 12-lead version, suggesting potential for use in simpler and more accessible clinical settings.

Unlike existing ECG-based tools that focus on detecting current disease, PULSE-HF is designed to forecast future deterioration. This predictive capability could help clinicians identify high-risk patients earlier and prioritize them for closer monitoring or intervention. Patients identified as lower risk may be able to reduce the frequency of hospital visits and testing, easing the burden on both patients and healthcare systems. The ability to use single-lead ECG data also opens the possibility of deploying the tool in resource-limited settings where advanced imaging, such as echocardiography, is not readily available.

The researchers plan to evaluate the model in prospective clinical studies involving real patients to confirm its predictive value in routine care. If validated, PULSE-HF could support more personalized management of heart failure by enabling earlier intervention and better allocation of healthcare resources, particularly in settings where access to specialized cardiac imaging is limited.

“The biggest thing that distinguishes [PULSE-HF] from other heart failure ECG methods is instead of detection, it does forecasting,” said Tiffany Yau, an MIT PhD student in Stultz’s lab who is also co-first author of the PULSE-HF paper.

Related Links:
MIT 
Mass General Brigham
Harvard Medical School


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Resorbable Bovine Collagen Membrane
GenDerm
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Artificial intelligence (AI) standalone performance and reader performance with versus without AI assistance. (A) Receiver operating characteristics (ROC) curve for AI standalone performance in the US dataset (AUC 0.899, 95% CI 0.858 to 0.939). (B) ROC curve for AI standalone performance in the Korean dataset (AUC 0.963, 95% CI 0.946 to 0.975). (C) Pooled reader ROC without (AUC 0.718) versus with (AUC 0.852) AI assistance in the Korean dataset; P<0.001. AUC, area under the receiver operating characteristics curve. (Leonard Sunwoo et al., Journal of NeuroInterventional Surgery (2026). DOI: 10.1136/jnis-2026-025339)

AI Improves Non-Contrast CT Interpretation for Time-Sensitive Stroke Assessment

Acute ischemic stroke occurs when a blood vessel in the brain becomes blocked, requiring rapid diagnosis to enable timely reperfusion therapy. Emergency departments often use computed tomography angiography... Read more

Surgical Techniques

view channel
Image: Researchers developed a handheld photothermal mid-infrared spectroscopic imaging (MIRSI) system that measures just 8 square inches. Probe light from a visible (red) diode laser and pump light from a modulated quantum cascade laser (QCL) are coupled into optical fibers and delivered to a flexible, handheld imager (blue dashed box). The beams are combined at a short-pass dichroic mirror and focused onto the sample using an off-axis parabolic mirror (OAP). (Image Credit:Rohith Reddy, University of Houston)

Handheld Infrared Imaging Device Supports Tumor Margin Assessment During Surgery

Accurately determining tumor margins during surgery remains challenging. Frozen-section pathology takes time and can miss residual disease, potentially leading to repeat surgery and delayed therapy.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.